Evidence map›Paper›PMID 26685679›Full record

ReviewEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2016

Salivary acinic cell carcinoma: reappraisal and update.

V Vander Poorten, A Triantafyllou, L D R Thompson, J Bishop, E Hauben, J Hunt, A Skalova, G Stenman, R P Takes, D R Gnepp and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Oncocytic salivary gland carcinomas.Histology and histopathology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
  14. Review
  15. Acinic cell carcinoma of the parotid gland: Timeo Danaos et dona ferentes? A multicenter retrospective analysis focusing on survival outcome.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Article
  16. Article
  17. Article
  18. Analysis of clinicopathologic features and expression of NR4A3 in sinonasal acinic cell carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

V Vander PoortenOtorhinolaryngology-Head and Neck Surgery and Leuven Cancer Institute, Department of Oncology-Section Head and Neck Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. vincent.vanderpoorten@uzleuven.be.ORCID http://orcid.org/0000-0003-1341-829X
A TriantafyllouSchool of Dentistry, University of Liverpool, Liverpool, UK.
L D R ThompsonSouthern California Permanente Medical Group, Woodland Hills, CA, USA.
J BishopDepartment of Pathology and Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
E HaubenDepartment of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
J HuntDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
A SkalovaDepartment of Pathology, Faculty of Medicine in Plzen, Charles, University Prague, Prague, Czech Republic.
G StenmanEuropean Salivary Gland Society, Geneva, Switzerland.
R P TakesDepartment of Otolaryngology-Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
D R GneppUniversity Pathologists, Fall River, MA, USA.
H HellquistDepartment of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
B WenigDepartment of Pathology, Beth Israel Medical Center, New York, NY, USA.
D BellDepartment of Pathology, MD Anderson Cancer Center, Houston, TX, USA.
A RinaldoUniversity of Udine School of Medicine, Udine, Italy.
A FerlitoCoordinator of the International Head and Neck Scientific Group, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiologic and clinicopathologic features, therapeutic strategies, and prognosis for acinic cell carcinoma of the major and minor salivary glands are critically reviewed. We explore histopathologic, histochemical, electron microscopic and immunohistochemical aspects and discuss histologic grading, histogenesis, animal models, and genetic events. In the context of possible diagnostic difficulties, the relationship to mammary analog secretory carcinoma is probed and a classification is suggested. Areas of controversy or uncertainty, which may benefit from further investigations, are also highlighted.

Indexed as

Carcinoma, Acinar CellAnimalsDiagnosis, DifferentialDisease Models, AnimalHumansMicroscopy, ElectronParotid GlandPreoperative CarePrognosisSalivary Gland NeoplasmsSalivary Glands, MinorAcinic cell carcinomaMammary analog secretory carcinomaPathologyPrognosisSalivary glandsTherapy

Identifiers

PMID26685679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.